
Professor Emeritus, Department of Psychiatry
Biosketch
Rajiv Tandon, MD, is Professor Emeritus of the Department of Psychiatry at the Western Michigan University Homer Stryker M.D. School of Medicine and a board-certified psychiatrist. He is a graduate of the All India Institute of Medical Sciences, New Delhi, India. He completed his residency in psychiatry at the National Institute of Mental Health and Neuro Sciences (NIMHANS) and at the University of Michigan Medical Center, Ann Arbor, Michigan. He subsequently obtained a Master's degree in Clinical Research Design and Statistical Analysis from the University of Michigan School of Public Health and a diploma in Management Development from the Harvard Business School. He served on the faculty in the Department of Psychiatry at the University of Michigan from 1987-2004; in addition, he served as the Director of the Schizophrenia Program from 1987-2000 and Director of the Hospital and Community Services Division from 1996-2000.
Dr. Tandon's principal research interests are in the neurobiology of schizophrenia, classification of psychiatric disorders (he served on the DSM-5 workgroup for psychotic disorders), and psychopharmacology. He has over 300 scientific publications and has received several national and international awards for research and training. He is Editor-in-Chief of the Asian Journal of Psychiatry and is the immediate Past-President of the Florida Psychiatric Society and the Florida chapter of the National Alliance on Mental Illness (NAMI).
-
Board Certification
- American Board of Psychiatry and Neurology (Psychiatry)
-
Education and Training
- Diploma 1998, Management Development, Harvard Business School, Harvard University
- MS 1993, Clinical Research Design and Statistical Analysis, University of Michigan-Ann Arbor
- Residency 1987, Psychiatry, Medical School, University of Michigan-Ann Arbor
- Residency 1983, Psychiatry, National Institute of Mental Health and Neuro Sciences
- MBBS 1980, Medicine, All India Institute of Medical Sciences
-
Research
- Schizophrenia and Disorders with Psychotic Features
- Neuropsychopharmacology
- Neurobiology
- DSM
-
Publications
Tandon R. Is 50–90 percent of all medical research unethical? The Helsinki Declaration Asian Journal of Psychiatry. 2025;104
Tandon R. Proper naming of medications used in psychiatric practice: Its time has come Asian Journal of Psychiatry. 2025;103
Franco D’Souza R., Surapaneni K.M., P S., Regupathy A., Mathew M., Mishra V., Kalaimathi A.G., Sekkizhar G., Tandon R., Louis Palatty P., Mady V. Convergence of Diverse Expertise: A Multidisciplinary Training on the Ethics of Artificial Intelligence in Healthcare Technology and Research Journal of Academic Ethics. 2024
Franco D’Souza R., Amanullah S., Mathew M., Tandon R., Surapaneni K.M. ChatGPT: A new horizon at the intersect of human and artificial intelligence in academic psychiatry Bipolar Disorders. 2024;26:393-394.
Keshavan M.S., Seif P., Tandon R. Muscarinic deficits - part of a cholinergic-dopaminergic- glutamatergic imbalance in schizophrenia? Schizophrenia Research. 2024;274:508-510.
Suryadevara U., Tan S., Venkatasubramaniam G., Tandon R. 2024 Articles of import and impact Asian Journal of Psychiatry. 2024;102
Tandon R. A pictorial series on the clinical neuroscience of psychiatry Asian Journal of Psychiatry. 2024;92
Tandon R. Asian Journal of Psychiatry, State of the Journal 2024: Forging Ahead Asian Journal of Psychiatry. 2024;93
Tandon R. Attenuated psychosis syndrome: Keeping up with advances in the field Asian Journal of Psychiatry. 2024;100
Tandon R. Computational psychiatry and the Asian Journal of Psychiatry Asian Journal of Psychiatry. 2024;95
Tandon R. Finally, a non-dopaminergic antipsychotic (xanomeline-trospium) for treatment of schizophrenia: Significance and learnings Asian Journal of Psychiatry. 2024;102
Tandon R. Public Mental Health: What role must and can a psychiatrist play Asian Journal of Psychiatry. 2024;98
Tandon R. Reinventing schizophrenia. Updating the construct a three-year international project Asian Journal of Psychiatry. 2024;97
Tandon R. Renaming schizophrenia – Why and why Not Asian Journal of Psychiatry. 2024;99
Tandon R. Suicide prevention: A public health imperative Asian Journal of Psychiatry Collection 2018–2024 Asian Journal of Psychiatry. 2024;96
Tandon R. The Asian Journal of Psychiatry turns sweet sixteen: An end of year review Asian Journal of Psychiatry. 2024;102
Tandon R., Keshavan M.S., Javed A., Rao G.P. The Gaza conflict and the role of psychiatry: A call to action Asian Journal of Psychiatry. 2024;98
Tandon R., Nasrallah H., Akbarian S., Carpenter W.T., DeLisi L.E., Gaebel W., Green M.F., Gur R.E., Heckers S., Kane J.M., Malaspina D., Meyer-Lindenberg A., Murray R., Owen M., Smoller J.W., Yassine W., Keshavan M. The schizophrenia syndrome, circa 2024: What we know and how that informs its nature Schizophrenia Research. 2024;264:1-28.
Keshavan M.S., Tandon R. Eastern perspectives on mind and healing: Lessons from the Vedas and the Gita Asian Journal of Psychiatry. 2023;85
Tandon R. Application of computational methods to the study of schizophrenia an exciting but treacherous frontier Asian Journal of Psychiatry. 2023;87
Tandon R. Asian Psychiatry, World Psychiatry, and the Asian Journal of Psychiatry: back to the future Asian Journal of Psychiatry. 2023
Tandon R. Asian philosophies and the practice of modern psychiatry Asian Journal of Psychiatry. 2023;86
Tandon R. Asian psychiatry, world psychiatry, and the Asian Journal of Psychiatry: Back to the future Asian Journal of Psychiatry. 2023;84
Tandon R. Computational psychiatry and the psychopathology of psychosis: Promising leads and blind alleys Schizophrenia Research. 2023;254:143-145.
Tandon R. Controversies in psychiatry practice and research Asian Journal of Psychiatry. 2023;81
Tandon R. Controversies in psychiatry practice and research: Identifying and properly addressing critical points of disagreement Asian Journal of Psychiatry. 2023;79
Tandon R. Mental health amidst wars and violent conflicts. Maintaining humanity, improving awareness, promoting sanity Asian Journal of Psychiatry. 2023;89
Tandon R. Modernizing undergraduate and postgraduate psychiatric education: an international imperative Asian Journal of Psychiatry. 2023;88
Tandon R. The Asian Journal of Psychiatry in a changing landscape of scientific psychiatric publishing: Accessibility, clarity, transparency Asian Journal of Psychiatry. 2023;85
Tandon R., Keshavan M., Nasrallah H. “Reinventing schizophrenia: Updating the construct”. Project update and next steps Schizophrenia Research. 2023;252:345-347.
Tandon R., Nasrallah H., Keshavan M. Advancing the understanding of the early stages of the schizophrenia syndrome: New opportunities to make a difference Asian Journal of Psychiatry. 2023;81
Thornton J., D'Souza R., Tandon R. Artificial intelligence and psychiatry research and practice Asian Journal of Psychiatry. 2023;81
Thornton J., Tandon R. Does machine-learning-based prediction of suicide risk actually reduce rates of suicide: A critical examination Asian Journal of Psychiatry. 2023;88
Fountoulakis K.N., Dragioti E., Theofilidis A.T., Wiklund T., Atmatzidis X., Nimatoudis I., Thys E., Wampers M., Hranov L., Hristova T., Aptalidis D., Milev R., Iftene F., Spaniel F., Knytl P., Furstova P., From T., Karlsson H., Walta M., Salokangas R.K.R., Azorin J.M., Bouniard J., Montant J., Juckel G., Haussleiter I.S., Douzenis A., Michopoulos I., Ferentinos P., Smyrnis N., Mantonakis L., Nemes Z., Gonda X., Vajda D., Juhasz A., Shrivastava A., Waddington J., Pompili M., Comparelli A., Corigliano V., Rancans E., Navickas A., Hilbig J., Bukelskis L., Stevovic L.I., Vodopic S., Esan O., Oladele O., Osunbote C., Rybakowski J.K., Wojciak P., Domowicz K., Figueira M.L., Linhares L., Crawford J., Panfil A.L., Smirnova D., Izmailova O., Lecic-Tosevski D., Temmingh H., Howells F., Bobes J., Garcia-Portilla M.P., García-Alvarez L., Erzin G., Karadağ H., De Sousa A., Bendre A., Hoschl C., Bredicean C., Papava I., Vukovic O., Pejuskovic B., Russell V., Athanasiadis L., Konsta A., Stein D., Berk M., Dean O., Tandon R., Kasper S., De Hert M. Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study CNS Spectrums. 2022;27:716-723.
Tandon R. Agreement on the contours of schizophrenia: The first order of business Schizophrenia Research. 2022;242:135-137.
Tandon R. Controversies in psychiatry practice and research. Asian Journal of Psychiatry, Circa 2023 Asian Journal of Psychiatry. 2022;78
Tandon R. Growing impact of the Asian Journal of Psychiatry greater responsibility and renewed commitment Asian Journal of Psychiatry. 2022;75
Tandon R. Moving beyond COVID Asian Journal of Psychiatry. 2022;73
Tandon R. Putting the cart before the horse. Schizophrenia does need a name change, but the time is not right Schizophrenia Research. 2022;240:22-23.
Tandon R., Greden J.F. Reconstructing schizophrenia: Lessons from major mood disorders Schizophrenia Research. 2022;242:42-44.
Tandon R., Keshavan M., Nasrallah H. Reinventing schizophrenia. Updating the construct Schizophrenia Research. 2022;242:1-3.
Fountoulakis K.N., Dragioti E., Theofilidis A.T., Wiklund T., Atmatzidis X., Nimatoudis I., Thys E., Wampers M., Hranov L., Hristova T., Aptalidis D., Milev R., Iftene F., Spaniel F., Knytl P., Furstova P., From T., Karlsson H., Walta M., Salokangas R.K.R., Azorin J.M., Bouniard J., Montant J., Juckel G., Haussleiter I.S., Douzenis A., Michopoulos I., Ferentinos P., Smyrnis N., Mantonakis L., Nemes Z., Gonda X., Vajda D., Juhasz A., Shrivastava A., Waddington J., Pompili M., Comparelli A., Corigliano V., Rancans E., Navickas A., Hilbig J., Bukelskis L., Stevovic L.I., Vodopic S., Esan O., Oladele O., Osunbote C., Rybakowski J.K., Wojciak P., Domowicz K., Figueira M.L., Linhares L., Crawford J., Panfil A.L., Smirnova D., Izmailova O., Lecic-Tosevski D., Temmingh H., Howells F., Bobes J., Garcia-Portilla M.P., García-Alvarez L., Erzin G., Karada H., De Sousa A., Bendre A., Hoschl C., Bredicean C., Papava I., Vukovic O., Pejuskovic B., Russell V., Athanasiadis L., Konsta A., Stein D., Berk M., Dean O., Tandon R., Kasper S., De Hert M. Modeling psychological function in patients with schizophrenia with the PANSS: An international multi-center study CNS Spectrums. 2021;26:290-298.
Fountoulakis K.N., Moeller H.J., Kasper S., Tamminga C., Yamawaki S., Kahn R., Tandon R., Correll C.U., Javed A. The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia CNS Spectrums. 2021;26:562-586.
Tandon R. Behind the scenes at the Asian Journal of Psychiatry 1. Initial Editorial Processing Asian Journal of Psychiatry. 2021;57
Tandon R. COVID-19 and suicide: Just the facts. Key learnings and guidance for action Asian Journal of Psychiatry. 2021;60
Tandon R. COVID-19 and the Asian Journal of Psychiatry: Keeping 2020 in the rear-view mirror Asian Journal of Psychiatry. 2021;56
Tandon R. The bitter lessons of COVID-19: Acknowledging and working through many points of tension Asian Journal of Psychiatry. 2021;55
Nathani M., Jaleel V., Turner A., Dirvonas C., Suryadevara U., Tandon R. When you hear hoofbeats, think horses and zebras: The importance of a wide differential when it comes to frontotemporal lobar degeneration Asian Journal of Psychiatry. 2020;47
Tandon R. Asian Journal of Psychiatry—Beginning a new decade Asian Journal of Psychiatry. 2020;47
Tandon R. COVID-19 and mental health: Preserving humanity, maintaining sanity, and promoting health Asian Journal of Psychiatry. 2020;51
Tandon R. The COVID-19 pandemic, personal reflections on editorial responsibility Asian Journal of Psychiatry. 2020;50
Tandon R., Lenderking W.R., Weiss C., Shalhoub H., Barbosa C.D., Chen J., Greene M., Meehan S.R., Duvold L.B., Arango C., Agid O., Castle D. Erratum: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: A worldwide, cross-sectional, web-based survey (Ann Gen Psychiatry (2020) 19 (42) DOI: 10.1186/s1299 1-020-00292-5) Annals of General Psychiatry. 2020;19
Tandon R., Lenderking W.R., Weiss C., Shalhoub H., Barbosa C.D., Chen J., Greene M., Meehan S.R., Duvold L.B., Arango C., Agid O., Castle D. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: A worldwide, cross-sectional, web-based survey Annals of General Psychiatry. 2020;19
Cardona D.J., Tandon R., Haskett R.F., Greden J.F. Menstrual Effects on Neuroendocrine Measures Menstruation, Health, And Illness. 2019:41-47.
Fountoulakis K.N., Dragioti E., Theofilidis A.T., Wikilund T., Atmatzidis X., Nimatoudis I., Thys E., Wampers M., Hranov L., Hristova T., Aptalidis D., Milev R., Iftene F., Spaniel F., Knytl P., Furstova P., From T., Karlsson H., Walta M., Salokangas R.K.R., Azorin J.M., Bouniard J., Montant J., Juckel G., Haussleiter I.S., Douzenis A., Michopoulos I., Ferentinos P., Smyrnis N., Mantonakis L., Nemes Z., Gonda X., Vajda D., Juhasz A., Shrivastava A., Waddington J., Pompili M., Comparelli A., Corigliano V., Rancans E., Navickas A., Hilbig J., Bukelskis L., Injac Stevovic L., Vodopic S., Esan O., Oladele O., Osunbote C., Rybakowski J., Wojciak P., Domowicz K., Figueira M.L., Linhares L., Crawford J., Panfil A.L., Smirnova D., Izmailova O., Lecic-Tosevski D., Temmingh H., Howells F., Bobes J., Garcia-Portilla M.P., García-Alvarez L., Erzin G., Karadaǧ H., De Sousa A., Bendre A., Hoschl C., Bredicean C., Papava I., Vukovic O., Pejuskovic B., Russell V., Athanasiadis L., Konsta A., Stein D., Berk M., Dean O., Tandon R., Kasper S., De Hert M. Staging of Schizophrenia with the Use of PANSS: An International Multi-Center Study International Journal of Neuropsychopharmacology. 2019;22:681-697.
Ramesh B., Tandon R. Bridging the Efficacy-Effectiveness Gap in the Antipsychotic Treatment of Schizophrenia: Back to the Basics Asian Journal of Psychiatry. 2019;40:A1-A2.
Tandon N., Tandon R. Machine learning in psychiatry- standards and guidelines Asian Journal of Psychiatry. 2019;44:A1-A4.
Tandon N., Tandon R. Using machine learning to explain the heterogeneity of schizophrenia. Realizing the promise and avoiding the hype Schizophrenia Research. 2019;214:70-75.
Tandon R., Keshavan M.S. Asian Psychiatry and the Asian Journal of Psychiatry Asian Journal of Psychiatry. 2019;43:A1-A2.
Tandon R., Shariff S.M. Substance-induced psychotic disorders and schizophrenia: Pathophysiological insights and clinical implications American Journal of Psychiatry. 2019;176:683-684.
Westerman P., Tandon R. Improving Neuroscience Literacy of Psychiatrists Asian Journal of Psychiatry. 2019;39:A1.
Wray A.M., Hoyt T., Welch S., Civetti S., Anthony N., Ballester E., Tandon R. Veterans Engaged in Treatment, Skills, and Transitions for Enhancing Psychiatric Safety (VETSTEPS) Psychiatric Rehabilitation Journal. 2019;42:277-283.
Bruijnzeel D., Tandon R. Antipsychotic Polypharmacy: State of the Science and Guidelines for Practice. It's difficult to stop once you start Asian Journal of Psychiatry. 2018;33:A1-A2.
Bruijnzeel D., Tandon R. Stop Chasing One's Tail: Resist the Practice of Treating Serial Side-Effects Asian Journal of Psychiatry. 2018;31:A1-A2.
Constantine R., Andel R., McPherson M., Tandon R. Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used? Psychiatry Research. 2018;263:238-244.
Suryadevara U., Tandon R. Decriminalization of Attempted Suicide across Asia- It Matters! Asian Journal of Psychiatry. 2018;35:A2-A3.
Tandon N., Tandon R. Will machine learning enable us to finally cut the gordian knot of schizophrenia Schizophrenia Bulletin. 2018;44(5):939-941.
Tandon R., Nathani M. Increasing Suicide Rates Across Asia- A Public Health Crisis Asian Journal of Psychiatry. 2018;36:A2-A4.
Tareen R.S., Tandon R. A stitch in time saves nine: Untreated perinatal depression hurts future generations Asian Journal of Psychiatry. 2018;38:A1-A3.
Thornton J.E., Tandon R. Learning Research Ethics; Why It Matters Asian Journal of Psychiatry. 2018;34:A2.
Blanchard J.J., Bradshaw K.R., Garcia C.P., Nasrallah H.A., Harvey P.D., Casey D., Csoboth C.T., Hudson J., Julian L., Lentz E., Nuechterlein K.H., Perkins D.O., Skale T.G., Snowden L.R., Tandon R., Tek C., Velligan D., Vinogradov S., O'Gorman C. Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study Schizophrenia Research. 2017;185:137-143.
Bruijnzeel D., Tandon R. Antipsychotic treatment of schizophrenia. We can do better Asian Journal of Psychiatry. 2017;28:A1-A2.
Greene L., Moreo K., Nasrallah H., Tandon R., Sapir T. Self-Reported Training Adequacy, Experience, and Comfort Level in Performing Schizophrenia-Related Clinical Skills among Psychiatry Residents and Fellows Academic Psychiatry. 2017;41(4):497-502.
Keshavan M., Lawler A.N., Nasrallah H.A., Tandon R. New drug developments in psychosis: Challenges, opportunities and strategies Progress in Neurobiology. 2017;152:3-20.
McIntyre R., Suppes T., Tandon R., Ostacher M. Florida Best Practice Psychotherapeutic Medication Guidelines for adults with major depressive disorder Journal of Clinical Psychiatry. 2017;78(6):703-713.
Suryadevara U., Bruijnzeel D.M., Nuthi M., Jagnarine D.A., Tandon R., Bruijnzeel A.W. Pros and cons of medical cannabis use by people with chronic brain disorders Current Neuropharmacology. 2017;15(6):800-814.
Tait L., Stein E., Turner A., Welch S., Tandon R. Worsening agitation and hallucinations: Could it be PTSD? Current Psychiatry. 2017;16(1):50-58.
Tandon R., Bruijnzeel D. Modelling schizophrenia: Opportunities and challenges Asian Journal of Psychiatry. 2017;25:A1.
Tandon R., Suryadevara U. Psycho-neuro-immuno-endocrinology of schizophrenia: Back to the future Asian Journal of Psychiatry. 2017;26:A1-A2.
Bruijnzeel D., Tandon R. Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression Drug Design, Development and Therapy. 2016;10:1641-1647.
Lee B., McPherson M.A., Tandon R., Singh S., Jones M.E., Becker E.R. Trends and intervention results for unusual antipsychotic polypharmacy prescribing patterns for Florida adult and child Medicaid population: 2007-2013: (Running title: " Unusual Florida Medicaid antipsychotic prescribing") Journal of Health Care Finance. 2016;42(4)
Ostacher M.J., Tandon R., Suppes T. Florida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: A novel, practical, patient-centered guide for clinicians Journal of Clinical Psychiatry. 2016;77(7):920-926.
Pierce A., Turner A., Gilbo N., Ginory A., Korah T., Tandon R. No evidence of pregnancy, but she is suicidal and depressed after 'my baby died' Current Psychiatry. 2016;15(7):67-68.
Tandon R. Conceptualizing psychotic disorders: Don't throw the baby out with the bathwater World Psychiatry. 2016;15(2):133-134.
Tandon R. DSM-5 dimensions of Schizophrenia enable measurement-based care to individualize pharmacological treatment Asian Journal of Psychiatry. 2016;24:A1-A2.
Tandon R., Bruijnzeel D.C.M. What psychiatrists must know to make the mandated transition to ICD-10 Current Psychiatry. 2016;15(1)
Tandon R., Carpenter W.T. Psychotic disorders in DSM-5: Clinical implications of revisions from DSM-IV Psychiatric Times. 2016;33(10)
Tandon R., Cucchiaro J., Phillips D., Hernandez D., Mao Y., Pikalov A., Loebel A. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia Journal of Psychopharmacology. 2016;30(1):69-77.
Bruijnzeel D., Yazdanpanah M., Suryadevara U., Tandon R. Lurasidone in the treatment of schizophrenia: A critical evaluation Expert Opinion on Pharmacotherapy. 2015;16(10):1559-1565.
Constantine R., Andel R., McPherson M., Tandon R. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial Schizophrenia Research. 2015;166(1-3):194-200.
Fountoulakis K.N., Gonda X., Baghai T.C., Baldwin D.S., Bauer M., Blier P., Gattaz W., Hasler G., Möller H.J., Tandon R., Vieta E., Kasper S. Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy International Journal of Psychiatry in Clinical Practice. 2015;19(3):158-167.
Keshavan M.S., Tandon R. On mentoring and being mentored Asian Journal of Psychiatry. 2015;16:84-86.
Nasrallah H.A., Harvey P.D., Casey D., Csoboth C.T., Hudson J., Julian L., Lentz E., Nuechterlein K.H., Perkins D.O., Kotowsky N., Skale T.G., Snowden L.R., Tandon R., Tek C., Velligan D., Vinogradov S., O'Gorman C. The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization Schizophrenia Research. 2015;166(1-3):69-79.
Tandon R. Bipolar and depressive disorders in diagnostic and statistical manual of mental disorders-5: Clinical implications of revisions from diagnostic and statistical manual of mental disorders-IV Indian Journal of Psychological Medicine. 2015;37(1):1-4.
Tandon R., Rankupalli B., Suryadevara U., Thornton J. Psychiatry is a clinical neuroscience, but how do we move the field? Asian Journal of Psychiatry. 2015;17:135-137.
Boutros N.N., Mucci A., Diwadkar V., Tandon R. Negative symptoms in schizophrenia: A comprehensive review of electrophysiological investigations Clinical Schizophrenia and Related Psychoses. 2014;8(1)
Bruijnzeel D., Suryadevara U., Tandon R. Antipsychotic treatment of schizophrenia: An update Asian Journal of Psychiatry. 2014;11:3-7.
Carpenter W.T., Regier D., Tandon R. Misunderstandings about Attenuated Psychosis Syndrome in the DSM-5 Schizophrenia Research. 2014;152(1):303.
Janicak P.G., Marder S.R., Tandon R., Goldman M. Conclusion Schizophrenia: Recent Advances in Diagnosis and Treatment. 2014:315-320.
Janicak P.G., Marder S.R., Tandon R., Goldman M. Introduction Schizophrenia: Recent Advances in Diagnosis and Treatment. 2014:3-12.
Janicak P.G., Tandon R., Marder S.R., Goldman M. Preface Schizophrenia: Recent Advances in Diagnosis and Treatment. 2014:vii-viii.
Janicak P.G., Tandon R., Marder S.R., Goldman M. Schizophrenia: Recent advances in diagnosis and treatment Schizophrenia: Recent Advances in Diagnosis and Treatment. 2014:1-331.
Tandon R. Bridging the efficacy-effectiveness gap in the antipsychotic treatment of schizophrenia: Back to the basics Journal of Clinical Psychiatry. 2014;75(11):e1321-e1322.
Tandon R. How to review a scientific paper Asian Journal of Psychiatry. 2014;11:124-127.
Tandon R. Schizophrenia and other psychotic disorders in diagnostic and statistical manual of mental disorders (DSM)-5: Clinical implications of revisions from DSM-IV Indian Journal of Psychological Medicine. 2014;36(3):223-225.
Tandon R., Bruijnzeel D. The evolving nosology of schizophrenia: Relevance for treatment Schizophrenia: Recent Advances in Diagnosis and Treatment. 2014:13-23.
Tandon R., Goldman M. Overview of neurobiology Schizophrenia: Recent Advances in Diagnosis and Treatment. 2014:27-33.
Barch D.M., Bustillo J., Gaebel W., Gur R., Heckers S., Malaspina D., Owen M.J., Schultz S., Tandon R., Tsuang M., Van Os J., Carpenter W. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: Relevance to DSM-5 Schizophrenia Research. 2013;150(1):15-20.
Carpenter W.T., Tandon R. Psychotic disorders in DSM-5. Summary of changes Asian Journal of Psychiatry. 2013;6(3):266-268.
Constantine R.J., McPherson M.A., Jones M.E., Tandon R., Becker E.R. Improving psychotherapeutic medication prescribing in Florida: Implementation of the florida medicaid drug therapy management program (MDTMP) Community Mental Health Journal. 2013;49(1):33-44.
Heckers S., Barch D.M., Bustillo J., Gaebel W., Gur R., Malaspina D., Owen M.J., Schultz S., Tandon R., Tsuang M., Van Os J., Carpenter W. Structure of the psychotic disorders classification in DSM-5 Schizophrenia Research. 2013;150(1):11-14.
Keshavan M., Tandon R., Nasrallah H. Renaming schizophrenia: Keeping up with the facts Schizophrenia Research. 2013;148(1-3):1-2.
Malaspina D., Owen M.J., Heckers S., Tandon R., Bustillo J., Schultz S., Barch D.M., Gaebel W., Gur R.E., Tsuang M., Van Os J., Carpenter W. Schizoaffective Disorder in the DSM-5 Schizophrenia Research. 2013;150(1):21-25.
Skidmore F.M., Yang M., Baxter L., von Deneen K., Collingwood J., He G., Tandon R., Korenkevych D., Savenkov A., Heilman K.M., Gold M., Liu Y. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease NeuroImage. 2013;81:484-495.
Tandon R. Definition of psychotic disorders in the DSM-5 too radical, too conservative, or just right! Schizophrenia Research. 2013;150(1):1-2.
Tandon R. Mood disorders in DSM-5: Best diagnoses today and a bridge to tomorrow Asian Journal of Psychiatry. 2013;6(4):279-280.
Tandon R. Optimizing outcomes for persons with schizophrenia minimizing adverse effects and individualizing treatment Asian Journal of Psychiatry. 2013;6(6):437-438.
Tandon R. Schizophrenia and other psychotic disorders in DSM-5: Clinical implications of revisions from DSM-IV Clinical Schizophrenia and Related Psychoses. 2013;7(1):16-19.
Tandon R. Some recent kernels of knowledge from the Indian Journal of Psychiatry Asian Journal of Psychiatry. 2013;6(1):90.
Tandon R. Schizophrenia spectrum and other psychotic disorders: DSM-5 revisions and their clinical implications Psychopharm Review. 2013;48(5):33-39.
Tandon R., Bruijnzeel D., Rankupalli B. Does change in definition of psychotic symptoms in diagnosis of schizophrenia in DSM-5 affect caseness? Asian Journal of Psychiatry. 2013;6(4):330-332.
Tandon R., Carpenter W.T. Psychotic disorders in DSM-5 Psychiatrie. 2013;10(1):5-9.
Tandon R., Gaebel W., Barch D.M., Bustillo J., Gur R.E., Heckers S., Malaspina D., Owen M.J., Schultz S., Tsuang M., Van Os J., Carpenter W. Definition and description of schizophrenia in the DSM-5 Schizophrenia Research. 2013;150(1):3-10.
Tandon R., Heckers S., Bustillo J., Barch D.M., Gaebel W., Gur R.E., Malaspina D., Owen M.J., Schultz S., Tsuang M., van Os J., Carpenter W. Catatonia in DSM-5 Schizophrenia Research. 2013;150(1):26-30.
Tsuang M.T., Van Os J., Tandon R., Barch D.M., Bustillo J., Gaebel W., Gur R.E., Heckers S., Malaspina D., Owen M.J., Schultz S., Carpenter W. Attenuated psychosis syndrome in DSM-5 Schizophrenia Research. 2013;150(1):31-35.
Fountoulakis K.N., Kasper S., Andreassen O., Blier P., Okasha A., Severus E., Versiani M., Tandon R., Möller H.J., Vieta E. Efficacy of pharmacotherapy in bipolar disorder: A report by the WPA section on pharmacopsychiatry European Archives of Psychiatry and Clinical Neuroscience. 2012;262(1 SUPPL.)
Poyurovsky M., Zohar J., Glick I., Koran L.M., Weizman R., Tandon R., Weizman A. Obsessive-compulsive symptoms in schizophrenia: Implications for future psychiatric classifications Comprehensive Psychiatry. 2012;53(5):480-483.
Tandon N., Shah J., Keshavan M., Tandon R. Attenuated psychosis and the schizophrenia prodrome: Current status of risk identification and psychosis prevention Neuropsychiatry. 2012;2(4):345-353.
Tandon R. Future directions in the treatment of schizophrenia Pharmacological Treatments in Schizophrenia. 2012:67-79.
Tandon R. Getting ready for DSM-5: Part 1 Current Psychiatry. 2012;11(2):33-37.
Tandon R. Getting ready for DSM-5: Psychotic disorders Current Psychiatry. 2012;11(4):1-4.
Tandon R. The Nosology of Schizophrenia. Toward DSM-5 and ICD-11. Psychiatric Clinics of North America. 2012;35(3):557-569.
Tandon R., Carpenter W.T. DSM-5 status of psychotic disorders: 1 year prepublication Schizophrenia Bulletin. 2012;38(3):369-370.
Bruijnzeel D., Tandon R. The concept of schizophrenia: From the 1850s to the DSM-5 Psychiatric Annals. 2011;41(5):289-295.
Clark A., Rankupalli B., Tandon R. Practicing evidence-based psychiatry. 3. Interpreting treatment guidelines Asian Journal of Psychiatry. 2011;4(4):304-308.
Constantine R.J., Tandon R., McPherson M., Andel R. Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's medicaid program Journal of Child and Adolescent Psychopharmacology. 2011;21(1):79-84.
Fayad S.M., Tandon R. Lurasidone: The most recent addition to our antipsychotic armamentarium Psychopharm Review. 2011;46(6):41-47.
Haj-Ibrahim J., Tandon R. Practicing evidence-based psychiatry- 2. Interpreting integrative literature: Systematic reviews and meta-analyses Asian Journal of Psychiatry. 2011;4(1):80-85.
Keshavan M.S., Nasrallah H.A., Tandon R. Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse Schizophrenia Research. 2011;127(1-3):3-13.
Nasrallah H., Tandon R., Keshavan M. Beyond the facts in schizophrenia: Closing the gaps in diagnosis, pathophysiology, and treatment Epidemiology and Psychiatric Sciences. 2011;20(4):317-327.
Tandon R. Antipsychotics in the treatment of schizophrenia: An overview Journal of Clinical Psychiatry. 2011;72(SUPPL. 1):4-8.
Tandon R. Race/ethnicity and outcomes in psychosis Asian Journal of Psychiatry. 2011;4(4):233.
Tandon R., Nasrallah H., Keshavan M. "Just the facts": Meandering in schizophrenia's many forests Schizophrenia Research. 2011;128(1-3):5-6.
Tandon R., Nasrallah H., Keshavan M. Antipsychotics, mortality and schizophrenia: What are the facts? Schizophrenia Research. 2011;133(1-3):262-263.
Constantine R.J., Andel R., Tandon R. Trends in adult antipsychotic polypharmacy: Progress and challenges in florida's medicaid program Community Mental Health Journal. 2010;46(6):523-530.
Constantine R.J., Boaz T., Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state medicaid program Clinical Therapeutics. 2010;32(5):949-959.
Heckers S., Tandon R., Bustillo J. Editorial: Catatonia in the DSM-shall we move or not? Schizophrenia Bulletin. 2010;36(2):205-207.
Jibson M.D., Tandon R. Drug treatment of secondary schizophrenia Secondary Schizophrenia. 2010:393-405.
Rankupalli B., Tandon R. Practicing evidence-based psychiatry: 1. Applying a study's findings: The threats to validity approach Asian Journal of Psychiatry. 2010;3(1):35-40.
Tandon R. DSM, ICD, and psychiatric nosology: How do cultural and national differences factor in? Asian Journal of Psychiatry. 2010;3(1):1-2.
Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "Just the Facts" 5. Treatment and prevention Past, present, and future Schizophrenia Research. 2010;122(1-3):1-23.
Tandon R., Rankapalli B. Comparative efficacy and safety of first-And second-generation antipsychotics in the treatment of schizophrenia: Facts and fiction Advances in Schizophrenia Research 2009. 2010:389-401.
Chen H., Tandon R. First- and second-generation antipsychotics and the concept of "atypicality" implications for clinical practice Psychopharm Review. 2009;44(11):81-88.
Keshavan M., Tandon R. Understanding evidence-based psychiatric practice and its application Asian Journal of Psychiatry. 2009;2(4):123.
Parks J., Radke A., Parker G., Foti M.E., Eilers R., Diamond M., Svendsen D., Tandon R. Principles of antipsychotic prescribing for policy makers, Circa 2008. Translating knowledge to promote individualized treatment Schizophrenia Bulletin. 2009;35(5):931-936.
Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization Schizophrenia Research. 2009;110(1-3):1-23.
Constantine R., Tandon R. Changing trends in pediatric antipsychotic use in florida's medicaid program Psychiatric Services. 2008;59(10):1162-1168.
Keshavan M.S., Tandon R., Boutros N.N., Nasrallah H.A. Schizophrenia, "just the facts": What we know in 2008. Part 3: Neurobiology Schizophrenia Research. 2008;106(2-3):89-107.
Möller H.J., Baldwin D.S., Goodwin G., Kasper S., Okasha A., Stein D., Tandon R., Versiani M., Malt U., Saletu B., Altamura A.C., Baron D., Bauer M., Belmaker R.H., Blier P., Boyer P., Bunney W.E., Burrows G., Fleischhacker W., Flores D., Gattaz W.F., Heinze G., Hindmarch I., Hippius H., Hoschl C., Kragh-Sorensen P., Lopez-Ibor J.J., Millet B., Min S., Monti J., Muller-Oerlinghausen B., Muller-Spahn F., Nutt D.J., Olie J.P., Paykel E.S., Racagni G., Renshaw P., Rosenberg R., Singh B., Vieta E., Zohar J. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: Consensus statement European Archives of Psychiatry and Clinical Neuroscience. 2008;258(SUPPL.3):3-23.
Parks J., Radke A., Tandon R. Impact of the CATIE findings on state mental health policy Psychiatric Services. 2008;59(5):534-536.
Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor J.J., Okasha A., Singh B., Stein D., Olie J.P., Fleischhacker W.W., Moeller H.J. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia Schizophrenia Research. 2008;100(1-3):20-38.
Tandon R., Javed A., Deva P., Weizman A., Kronfol Z., D'Souza R., Gangadhar B.N., Kapur S., Akiskal H., Tsuang M., Keshavan M. Disaster mental health in Asia and the Asian Journal of Psychiatry Asian Journal of Psychiatry. 2008;1(1):5-6.
Tandon R., Keshavan M., Nasrallah H. Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology Schizophrenia Research. 2008;102(1-3):1-18.
Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "Just the Facts": What we know in 2008. Part 1: Overview Schizophrenia Research. 2008;100(1-3):4-19.
Tandon R., Maj M. Nosological status and definition of schizophrenia: Some considerations for DSM-V and ICD-11 Asian Journal of Psychiatry. 2008;1(2):22-27.
Raedler T.J., Bymaster F.P., Tandon R., Copolov D., Dean B. Towards a muscarinic hypothesis of schizophrenia Molecular Psychiatry. 2007;12(3):232-246.
Tandon R. Antipsychotic treatment of schizophrenia: Two steps forward, one step back Current Psychiatry Reports. 2007;9(4):263-264.
Tandon R. Schizophrenia - Optimizing individual outcomes in schizophrenia: challenges and opportunities Psychiatric Times. 2007;24(2):18.
Tandon R., Carpenter W., Davis J. First- and second-generation antipsychotics: Learning from CUtLASS and CATIE [1] Archives of General Psychiatry. 2007;64(8):977-978.
Constantine R., Richard S., Surles R., Medvedeff D., Dewan N., Mann L., Williamson J., Tandon R. Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist Current Psychosis and Therapeutics Reports. 2006;4(1):5-11.
Raedler T., Tandon R. Cholinergic mechanisms in schizophrenia: Current concepts Current Psychosis and Therapeutics Reports. 2006;4(1):20-26.
Tandon R. Comparing antipsychotic efficacy [8] American Journal of Psychiatry. 2006;163(9):1645.
Tandon R. Pharmacologic treatment of schizophrenia: Current status and future trends Current Psychosis and Therapeutics Reports. 2006;4(1):40-49.
Tandon R., Marcus R.N., Stock E.G., Riera L.C., Kostic D., Pans M., McQuade R.D., Nyilas M., Iwamoto T., Crandall D.T. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) Schizophrenia Research. 2006;84(1):77-89.
Tandon R., Nasrallah H. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses [1] Archives of General Psychiatry. 2006;63(8):935-937.
Tandon R., Targum S.D., Nasrallah H.A., Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia Journal of Psychiatric Practice. 2006;12(6):348-363.
Nasrallah H.A., Targum S.D., Tandon R., McCombs J.S., Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia Psychiatric Services. 2005;56(3):273-282.
Tandon R. Suicidal behavior in schizophrenia Expert Review of Neurotherapeutics. 2005;5(1):95-99.
Tandon R., DeVellis R.F., Han J., Li H., Frangou S., Dursun S., Beuzen J.N., Carson W., Corey-Lisle P.K., Falissard B., Jody D.N., Kujawa M.J., L'Italien G., Marcus R.N., McQuade R.D., Ray S., Van Peborgh P. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder Psychiatry Research. 2005;136(2-3):211-221.
Tandon R., Jibson M.D. Comparing efficacy of first-line atypical antipsychotics: No evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole International Journal of Psychiatry in Clinical Practice. 2005;9(3):204-212.
Tandon R., Wolfgang Fleischhacker W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment Schizophrenia Research. 2005;79(2-3):145-155.
Payne J., Tandon R. A new millennium in the antipsychotic treatment of patients with bipolar disorder Advanced Studies in Medicine. 2004;4(10 F)
Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia Human Psychopharmacology. 2004;19(8):559-563.
Tandon R. Risperidone improves severe tardive dyskinesia in people with schizophrenia: Commentary Evidence-Based Mental Health. 2004;7(3):83.
Tandon R., Jibson M.D. PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIA Textbook of Biological Psychiatry. 2004:299-317.
Glick I.D., Carter W., Tandon R. A paradigm for treatment of inpatient psychiatric disorders: From asylum to intensive care Journal of Psychiatric Practice. 2003;9(5):395-402.
Tandon R. Improvement without impairment: A review of clinical data for quetiapine in the treatment of schizophrenia Journal of Clinical Psychopharmacology. 2003;23(3 SUPPL. 1)
Tandon R., Halbreich U. The second-generation 'atypical' antipsychotics: Similar improved efficacy but different neuroendocrine side effects Psychoneuroendocrinology. 2003;28(SUPPL. 1):1-7.
Tandon R., Jibson M. Suicidal behavior in schizophrenia: Diagnosis, neurobiology, and treatment implications Current Opinion in Psychiatry. 2003;16(2):193-197.
Tandon R., Jibson M.D. Efficacy of newer generation antipsychotics in the treatment of schizophrenia Psychoneuroendocrinology. 2003;28(SUPPL. 1):9-26.
Nasrallah H., Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia Journal of Clinical Psychiatry. 2002;63(SUPPL. 13):12-20.
Tandon R. Safety and tolerability: How do newer generation "atypical" antipsychotics compare? Psychiatric Quarterly. 2002;73(4):297-311.
Tandon R., Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: Scope of problem and impact on outcome Annals of Clinical Psychiatry. 2002;14(2):123-129.
Aziz M., Maixner D.F., DeQuardo J., Aldridge A., Tandon R. ECT and mental retardation: A review and case reports Journal of ECT. 2001;17(2):149-152.
Marcus S.M., Barry K.L., Flynn H.A., Tandon R., Greden J.F. Treatment guidelines for depression in pregnancy International Journal of Gynecology and Obstetrics. 2001;72(1):61-70.
Marcus S.M., Barry K.L., Flynn H.A., Tandon R., Greden J.F. Treatment guidelines for depression in pregnancy Giornale Italiano di Ostetricia e Ginecologia. 2001;23(9):411-420.
Rajarethinam R., DeQuardo J.R., Miedler J., Arndt S., Kirbat R., A. Brunberg J., Tandon R. Hippocampus and amygdala in schizophrenia: Assessment of the relationship of neuroanatomy to psychopathology Psychiatry Research - Neuroimaging. 2001;108(2):79-87.
Rajarethinam R., Miedler J., DeQuardo J., Irma Smet C., Brunberg J., Kirbat R., Tandon R. Prevalence of cavum septum pellucidum in schizophrenia studied with mri Schizophrenia Research. 2001;48(2-3):201-205.
Tandon R., DeQuardo J.R., Taylor S.F., McGrath M., Jobson M., Eiser A., Goldman M. Erratum: Phasic and enduring negative symptoms in schizophrenia: Biological markers and relationship to outcome (Schizophrenia Research (2000) 45 (191-201) PII: S0920996499001632) Schizophrenia Research. 2001;51(2-3):185.
Tandon R., Jibson M. Pharmacologic treatment of schizophrenia: What the future holds CNS Spectrums. 2001;6(12):980-986.
Tapp A., Kilzieh N., Wood A., Raskind M., Tandon R. Depression in patients with schizophrenia during an acute psychotic episode Comprehensive Psychiatry. 2001;42(4):314-318.
Guthrie S.K., Manzey L., Scott D., Giordani B., Tandon R. Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers Journal of Clinical Psychopharmacology. 2000;20(1):77-83.
Rajarethinam R.P., DeQuardo J.R., Nalepa R., Tandon R. Superior temporal gyrus in schizophrenia: A volumetric magnetic resonance imaging study Schizophrenia Research. 2000;41(2):303-312.
Tandon R. British journal of clinical pharmacology, supplement: introduction British Journal of Clinical Pharmacology, Supplement. 2000;49(SUPPL. 1)
Tandon R. Introduction British Journal of Clinical Pharmacology. 2000;49(SUPPL. 1)
Tandon R. Introduction. Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics. British journal of clinical pharmacology. 2000;49 Suppl 1
Tandon R., DeQuardo J.R., Taylor S.F., McGrath M., Jibson M., Eiser A., Goldman M. Phasic and enduring negative symptoms in schizophrenia: Biological markers and relationship to outcome Schizophrenia Research. 2000;45(3):191-201.
Taylor S.F., Koeppe R.A., Tandon R., Zubieta J.K., Frey K.A. In vivo measurement of the vesicular monoamine transporter in schizophrenia Neuropsychopharmacology. 2000;23(6):667-675.
Angrist B.M., Baldessarini R.J., Bowers M.B., Buchanan R.W., Caroff S.N., Casey D.E., Chouinard G., Cole J.O., Conley R.R., Csernansky J., Daniel D., Davidson M., Davis J., Davis K.L., DeLisi L., Fenton W.S., Freedman R., Friedhoff A.J., Ganguli R., Garver D.L., Gilmore J.H., Goff D.C., Hirschowitz J., Karson C., Keck J., Keshavan M.S., Krystal J., Levinson D.F., Lindenmayer J.P., Lohr J.B., Luchins D.J., Manschreck T., McGlashan T., Mendelowitz A., Miller D.D., Munetz M.R., Nasrallah H.A., Ninan P.T., Opler L.A., Owen R.R., Rifkin A., Risch S.C., Seeman M.V., Siever L.J., Simpson G.M., Siris S.G., Small J.G., Smith R.C., Smith T.E., Tandon R., Targum S.D., Volavka J., Wolkin A., Wolkowitz O.M., Wyatt R., Zarate J., Zimbroff D., Anderson C., Ascher- Svanum H., Astrachan B., Beels C.C., Bellack A.S., Bisbee C., Bond G.R., Bradshaw W., Brekke J., Carling P.J., Casper E.S., Caton C.L.M., Corrigan P.W., Davidson L., Diamond R., Dincin J., Dixon L., Drake R.E., Estroff S., Flesher S., Forquer S., Frank A., Furst A., Goldman C., Goldman H., Griffin-Francell C., Halford W.K., Hall L.L., Harvey R.B., Hoge M., Jaeger J., Kanter J., Lahti A.C., Lamb H.R., Lefley H.P., Libermann R.P., Littrell K.H., McCoy M., McFarlane W.R., Mellen V., Moller M.D., Mosher L.R. Treatment of schizophrenia 1999 Journal of Clinical Psychiatry. 1999;60(SUPPL. 11):3-80.
DeQuardo J.R., Keshavan M.S., Bookstein F.L., Bagwell W.W., Green W.D.K., Sweeney J.A., Haas G.L., Tandon R., Schooler N.R., Pettegrew J.W. Landmark-based morphometric analysis of first-episode schizophrenia Biological Psychiatry. 1999;45(10):1321-1328.
Earnst K.S., Taylor S.F., Smet I.C., Goldman R.S., Tandon R., Berent S. The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia [1] Schizophrenia Research. 1999;40(3):255-261.
Goldman M., DeQuardo J., Tandon R., Taylor S., Jibson M. Symptom correlates of global measures of severity in schizophrenia Comprehensive Psychiatry. 1999;40(6):458-461.
Kales H.C., Dequardo J.R., Tandon R. Combined electroconvulsive therapy and clozapine in treatment -resistant schizophrenia Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1999;23(3):547-556.
Maixner S., Mellow A., Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly Journal of Clinical Psychiatry. 1999;60(SUPPL. 8):29-41.
Tandon R. Cholinergic aspects of schizophrenia British Journal of Psychiatry. 1999;174(37):7-11.
Tandon R. Moving beyond findings: Concepts and model-building in schizophrenia Journal of Psychiatric Research. 1999;33(6):467-471.
Tandon R., Milner K., Jibson M.D. Antipsychotics from theory to practice: Integrating clinical and basic data Journal of Clinical Psychiatry. 1999;60(SUPPL. 8):21-28.
Tandon R., Taylor S.F., Dequardo J.R., Eiser A., Jibson M.D., Goldman M. The cholinergic system in schizophrenia reconsidered: Anticholinergic modulation of sleep and symptom profiles Neuropsychopharmacology. 1999;21(6):S189-S202.
Taylor S.F., Liberzon I., Tandon R., Decker L.R., Koeppe R.A. Differential modulation of visual cortex to complex visual stimuli in schizophrenic patients NeuroImage. 1999;9(6 PART II)
Taylor S.F., Tandon R., Koeppe R.A. Global cerebral blood flow increase reveals focal hypoperfusion in schizophrenia Neuropsychopharmacology. 1999;21(3):368-371.
DeQuardo J.R., Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? Journal of Psychiatric Research. 1998;32(3-4):229-242.
Jibson M.D., Tandon R. New atypical antipsychotic medications Journal of Psychiatric Research. 1998;32(3-4):215-228.
Maixner S., Tandon R., Eiser A., Taylor S., DeQuardo J., Shipley J. Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: A replication and extension American Journal of Psychiatry. 1998;155(11):1600-1602.
Tandon R. Impact of antipsychotic treatment on long-term course of schizophrenic illness: An introduction Journal of Psychiatric Research. 1998;32(3-4):119-120.
Tandon R. In conclusion: Does antipsychotic treatment modify the longterm course of schizophrenic illness? Journal of Psychiatric Research. 1998;32(3-4):251-253.
Taylor S.F., Huang G., Tandon R., Koeppe R.A. Letter naming among distracters activates anterior cingulate cortex in a selective attention task NeuroImage. 1998;7(4 PART II)
DeQuardo J., Goldman M., Tandon R. Erratum: VBR in schizophrenia. Relationship to family history of psychosis and season of birth (Schizophrenia Research 20 (1996) (275-285)) Schizophrenia Research. 1997;25(2):167.
DeQuardo J.R., Tomori O., Brunberg J.A., Tandon R. Does neuroanatomy predict ECT response? Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1997;21(8):1339-1352.
Grunhaus L., Shipley J.E., Eiser A., Pande A.C., Tandon R., Krahn D.D., Demitrack M.A., Remen A., Hirschmann S., Greden J.F. Sleep-onset rapid eye movement after electroconvulsive therapy is more frequent in patients who respond less well to electroconvulsive therapy Biological Psychiatry. 1997;42(3):191-200.
Guthrie S.K., Hariharan M., Kumar A., Bader G., Tandon R. The effect of paroxetine on thiothixene pharmacokinetics Journal of Clinical Pharmacy and Therapeutics. 1997;22(3):221-226.
Kales H., Raz J., Tandon R., Maixner D., Dequardo J., Miller A., Becks L. Relationship of seizure duration to antidepressant efficacy in electroconvulsive therapy Psychological Medicine. 1997;27(6):1373-1380.
Lewis C., DeQuardo J., DuBose C., Tandon R. Acute angle-closure glaucoma and paroxetine [2] Journal of Clinical Psychiatry. 1997;58(3):123-124.
Lewis C.F., DeQuardo J.R., Tandon R. Dystonia associated with trazodone and sertraline [11] Journal of Clinical Psychopharmacology. 1997;17(1):64-65.
Taylor S., Tandon R., Koeppe R. PET study of greater visual activation in schizophrenia American Journal of Psychiatry. 1997;154(9):1296-1298.
DeQuardo J.R., Bookstein F.L., Green W.D.K., Brunberg J.A., Tandon R. Spatial relationships of neuroanatomic landmarks in schizophrenia Psychiatry Research - Neuroimaging. 1996;67(1):81-95.
DeQuardo J.R., Goldman M., Tandon R. VBR in schizophrenia: Relationship to family history of psychosis and season of birth Schizophrenia Research. 1996;20(3):275-285.
Ghaziuddin N., King C.A., Naylor M.W., Ghaziuddin M., Chaudhary N., Giordani B., Dequardo J.R., Tandon R., Greden J. Electroconvulsive treatment in adolescents with pharmacotherapy-refractory depression Journal of Child and Adolescent Psychopharmacology. 1996;6(4):259-271.
Goldman M., Tandon R., DeQuardo J., Taylor S., Goodson J., McGrath M. Biological predictors of 1-year outcome in schizophrenia in males and females Schizophrenia Research. 1996;21(2):65-73.
Goldman M., Tandon R., Taylor S., DeQuardo J., Shipley J., Patel B., Reddig S., Jibson M. Dexamethasone nonsuppression and short Rapid Eye Movement latency in schizophrenia: Markers of an affective diathesis? Biological Psychiatry. 1996;40(9):927-929.
Grunhaus L., Shipley J.E., Eiser A., Pande A.C., Tandon R., Remen A., Greden J.F. Polysomnographic studies in patients referred for ECT: Pre-ECT studies Convulsive Therapy. 1996;12(4):224-231.
Hariharan U., Hariharan M., Naickar J.S., Tandon R. Determination of clozapine and its two major metabolites in human serum by liquid chromatography using ultraviolet detection Journal of Liquid Chromatography and Related Technologies. 1996;19(15):2409-2417.
Himelhoch S., Taylor S.F., Goldman R.S., Tandon R. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes Biological Psychiatry. 1996;39(3):227-229.
Lewis C.F., DeQuardo J.R., Tandon R. ECT in genetically confirmed Huntington's disease Journal of Neuropsychiatry and Clinical Neurosciences. 1996;8(2):209-210.
Lewis C.F., Tandon R., Shipley J.E., DeQuardo J.R., Jibson M., Taylor S.F., Goldman M. Biological predictors of suicidality in schizophrenia Acta Psychiatrica Scandinavica. 1996;94(6):416-420.
Tandon R., Lewis C., Taylor S., Shipley J., DeQuardo J., Jibson M., Goldman M. Relationship between DST nonsuppression and shortened REM latency in schizophrenia Biological Psychiatry. 1996;40(7):660-663.
Taylor S.F., Kornblum S., Tandon R. Facilitation and interference of selective attention in schizophrenia Journal of Psychiatric Research. 1996;30(4):251-259.
Bader G., Silk K.R., Dequardo J.R., Tandon R. Electroconvulsive therapy and intracranial aneurysm Convulsive Therapy. 1995;11(2):139-143.
DeQuardo J.R., Goldman R.S., Tandon R., McGrath-Giroux M., Kim L. Comparison of indices of premorbid function in schizophrenia Schizophrenia Research. 1995;15(3):283-290.
Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V., Baldessarini R.J., Viguera A.C., Carpenter W.T., Tamminga C.A., Greden J.F., Tandon R., Meltzer H.Y., Nuechterlein K.H., Gitlin M.J., Subotnik K.L., Wyatt R.J. Neuroleptic withdrawal in schizophrenic patients: A review of the literature Archives of General Psychiatry. 1995;52(3):173-212.
Greden J., Tandon R. Long-term Treatment for Lifetime Disorders? Archives of General Psychiatry. 1995;52(3):197-200.
Hansen-Grant S., Tandon R., Maixner D., DeQuardo J., Mahapatra S. Subclinical status epilepticus following ECT Convulsive Therapy. 1995;11(2):134-138.
Salah R.S., DeQuardo J.R., Jibson M.D., Carli T., Tandon R. Tinnitus and ECT Convulsive Therapy. 1995;11(2):122-125.
Tandon R. Neurobiological substrate of dimensions of schizophrenic illness Journal of Psychiatric Research. 1995;29(4):255-260.
Tandon R., Dequardo J., Goff D. Treatment of schizophrenia with anticholinergic medications [10] American Journal of Psychiatry. 1995;152(5):814-815.
DeQuardo J.R., Carpenter C.F., Tandon R. Patterns of substance abuse in Schizophrenia: Nature and significance Journal of Psychiatric Research. 1994;28(3):267-275.
DeQuardo J.R., Tandon R., Goldman R., Meador-Woodruff J.H., McGrath-Giroux M., Brunberg J.A., Kim L. Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia Biological Psychiatry. 1994;35(8):517-524.
Dequardo J.R., Tandon R., Fricchione G.L., Sedler M., Walker E. Index of affective flattening derived from examination of home movies of preschizophrenic individuals [6] American Journal of Psychiatry. 1994;151(11):1717-1718.
Grunhaus L., Shipley J.E., Eiser A., Pande A.C., Tandon R., Remen A., Greden J.F. Shortened REM latency PostECT is associated with rapid recurrence of depressive symptomatology Biological Psychiatry. 1994;36(4):214-222.
Grunhaus L., Shipley J.E., Eiser A., Remen A., Pande A.C., Tandon R., Greden J.F. Sleep Electroencephalographic Studies After ECT: Age and Clinical Response American Journal of Geriatric Psychiatry. 1994;2(1):39-51.
Aldrich M.S., Shipley J.E., Tandon R., Kroll P.D., Brower K.J. Sleep‐Disordered Breathing in Alcoholics: Association with Age Alcoholism: Clinical and Experimental Research. 1993;17(6):1179-1183.
Gillin J.C., Dow B.M., Thompson P., Parry B., Tandon R., Benca R. Sleep in depression and other psychiatric disorders Clinical Neuroscience. 1993;1(2):90-96.
Goldman R., Axelrod B.N., Tandon R., Berent S. Spurious WAIS-R cholinergic profiles in schizophrenia Clinical Neuropsychologist. 1993;7(2):171-178.
Goldman R.S., Axelrod B., Tandon R., Ribeiro S.C.M., Craig K., Berent S. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia Psychopathology. 1993;26(3-4):122-126.
Mann N.A., Tandon R., Butler J., Boyd M., Eisner W.H., Lewis M. Psychosocial rehabilitation in schizophrenia: Beginnings in acute hospitalization Archives of Psychiatric Nursing. 1993;7(3):154-162.
Patel B., Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment [1] American Journal of Psychiatry. 1993;150(5):836.
Reddig S., Minnema A.M., Tandon R. Neuroleptic malignant syndrome and clozapine Annals of Clinical Psychiatry. 1993;5(1):25-27.
Ribeiro S.C.M., Tandon R., Grunhaus L., Greden J.F. The DST as a predictor of outcome in depression: A meta-analysis American Journal of Psychiatry. 1993;150(11):1618-1629.
Tandon R., Goldman R., DeQuardo J.R., Goldman M., Perez M., Jibson M. Positive and negative symptoms covary during clozapine treatment in schizophrenia Journal of Psychiatric Research. 1993;27(4):341-347.
Tandon R., Greden J.F., Haskett R.F. Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls Schizophrenia Research. 1993;9(1):19-23.
Tandon R., Kane J. Neuropharmacologic Basis for Clozapine's Unique Profile Archives of General Psychiatry. 1993;50(2):158-159.
Tandon R., Ribeiro S.C.M., DeQuardo J.R., Goldman R.S., Goodson J.A., Greden J.F. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication Biological Psychiatry. 1993;34(7):495-497.
Tapp A., Tandon R., Scholten R., Dudley E. Age disorientation in kraepelinian schizophrenia: Frequency and clinical correlates Psychopathology. 1993;26(3-4):225-228.
DeQuardo J., Liberzon I., Tandon R. Recurrent post-ECT dyskinesia [3] Convulsive Therapy. 1992;8(1):42-43.
Dibble L., Tandon R. Post-ECT myoclonic jerks in a depressed patient with bulimia Convulsive Therapy. 1992;8(4):285-289.
Goldman R., Tandon R., Liberzon I., Greden J.F. Measurement of depression and negative symptoms in schizophrenia Psychopathology. 1992;25(1):49-56.
Ribeiro S.C.M., Tandon R., Ricoy R., Mazzara C., Craig K.A., Greden J.F. Clinical predictors of 1-year outcome in schizophrenia Psychopathology. 1992;25(6):331-334.
Shipley J., Schteingart D., Tandon R., Starkman M. Sleep architecture and sleep apnea in patients with Cushing's disease Sleep. 1992;15(6):514-518.
Shipley J.E., Schteingart D.E., Tandon R., Pande A.C., Grunhaus L., Haskett R.F., Starkman M.N. EEG sleep in cushing's disease and cushing's syndrome: comparison with patients with major depressive disorder Biological Psychiatry. 1992;32(2):146-155.
Tandon R., DeQuardo J.R., Goodson J., Mann N.A., Greden J.F. Effect of anticholinergics on positive and negative symptoms in schizophrenia Psychopharmacology Bulletin. 1992;28(3):297-302.
Tandon R., Shipley J.E., Taylor S., Greden J.F. Sleep abnormalities in schizophrenia: cholinergic contribution. Clinical neuropharmacology. 1992;15 Suppl 1 Pt A
Tandon R., Shipley J.E., Taylor S., Greden J.F., Eiser A., DeQuardo J., Goodson J. Electroencephalographic Sleep Abnormalities in Schizophrenia: Relationship to Positive/Negative Symptoms and Prior Neuroleptic Treatment Archives of General Psychiatry. 1992;49(3):185-194.
Taylor S.F., Goldman R.S., Tandon R., Shipley J.E. Neuropsychological function and REM sleep in schizophrenic patients Biological Psychiatry. 1992;32(6):529-538.
Albucher R.C., DeQuardo J., Tandon R. Treatment of catatonia with an anticholinergic agent Biological Psychiatry. 1991;29(5):513-514.
Goldman R., Axelrod B.N., Tandon R., Berent S. Analysis of executive functioning in schizophrenics using the wisconsin card sorting test Journal of Nervous and Mental Disease. 1991;179(8):507-508.
Goldman R.S., Tandon R., Liberzon I., Goodson J.A., Greden J.F. Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia Psychopathology. 1991;24(4):247-252.
Hariharan M., Van Noord T., Kindt E., Tandon R. A simple, sensitive liquid chromatographic assay of cis-thiothixene in plasma with coulometric detection Therapeutic Drug Monitoring. 1991;13(1):79-85.
Liberzon I., DeQuardo J.R., Sidell G., Mazzara C., Tandon R. Post-ECT dyskinesia Convulsive Therapy. 1991;7(1):40-44.
Panzer M.J., Tandon R. Bipolar disorder associated with turner’s syndrome Journal of Nervous and Mental Disease. 1991;179(11):702.
Tandon R., Goldman R.S., Greden J.F. Response Biological Psychiatry. 1991;29(6):621.
Tandon R., Greden J.F. Abnormal phosphoinositide turnover in schizophrenia Biological Psychiatry. 1991;29(3):295.
Tandon R., Greden J.F. Negative symptoms of schizophrenia: The need for conceptual clarity Biological Psychiatry. 1991;30(4):321-325.
Tandon R., Haskett R.F., Cardona D., Alcser K., Greden J.F. Menstrual cycle effects on the dexamethasone suppression test in major depression Biological Psychiatry. 1991;29(5):485-488.
Tandon R., Mazzara C., DeQuardo J., Craig K.A., Meador-Woodruff J.H., Goldman R., Greden J.F. Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome Biological Psychiatry. 1991;29(10):953-964.
Tandon R., Shipley J.E., Greden J.F., Mann N.A., Eisner W.H., Goodson J.A. Muscarinic cholinergic hyperactivity in schizophrenia. relationship to positive and negative symptoms Schizophrenia Research. 1991;4(1):23-30.
Taylor S.F., Tandon R., Shipley J.E., Eiser A.S. Effect of neuroleptic treatment on polysomnographic measures in schizophrenia Biological Psychiatry. 1991;30(9):904-912.
Taylor S.F., Tandon R., Shipley J.E., Eiser A.S., Goodson J.A. Sleep onset REM periods in schizophrenic patients Biological Psychiatry. 1991;30(2):205-209.
Panzer M., Tandon R., Greden J.F. Benzodiazepines and catatonia Biological Psychiatry. 1990;28(2):178-179.
Tandon R., Goldman R., Goodson J.A., Greden J.F. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia Biological Psychiatry. 1990;27(12):1323-1326.
Tandon R., Mann N.A., Eisner W.H., Coppard N. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients Psychiatry Research. 1990;31(3):235-241.
DeQuardo J.R., Tandon R. Hemifacial flushing during unilateral ECT: an alternative explanation. The American journal of psychiatry. 1989;146(3):412-413.
Hariharan M., Kindt E., Van Noord T., Tandon R. An improved sensitive assay for simultaneous determination of plasma haloperidol and reduced haloperidol levels by liquid chromatography using a coulometric detector Therapeutic Drug Monitoring. 1989;11(6):701-707.
Modell J.G., Tandon R., Beresford T.P. Dopaminergic activity of the antimuscarinic antiparkinsonian agents Journal of Clinical Psychopharmacology. 1989;9(5):347-351.
Shettar S., Grunhaus L., Pande A., Tandon R., Kronfol Z., Haskett R. Protective effects of intramuscular glycopyrrolate on cardiac conduction during ECT Convulsive Therapy. 1989;5(4):349-352.
Tandon R. Letters to the Editor Acta Psychiatrica Scandinavica. 1989;80(5):524-525.
Tandon R., Dutchak D., Greden J.F. Cholinergic syndrome following anticholinergic withdrawal in a schizophrenic patient abusing marijuana British Journal of Psychiatry. 1989;154(MAY):712-714.
Tandon R., Greden J. Cholinergic Hyperactivity and Negative Schizophrenic Symptoms: A Model of Cholinergic/Dopaminergic Interactions in Schizophrenia Archives of General Psychiatry. 1989;46(8):745-753.
Tandon R., Greden J.F. Positive and negative syndromes in schizophrenia. The American journal of psychiatry. 1989;146(3):407.
Tandon R., Mazzara C., Dequardo J.R. The DST and outcome in schizophrenia American Journal of Psychiatry. 1989;146(12):1648-1649.
Tandon R., Shipley J., Eiser A., Greden J. Association between abnormal REM sleep and negative symptoms in schizophrenia Psychiatry Research. 1989;27(3):359-361.
Tandon R., Silk K., Greden J., Goodson J., Hariharan M., Meador-Woodruff J., Kronfol Z. Positive and negative symptoms in schizophrenia and the dexamethasone suppression test Biological Psychiatry. 1989;25(6):788-792.
DeQuardo J., Tandon R. Concurrent lithium therapy prevents ECT-induced switch to mania. Journal of Clinical Psychiatry. 1988;49(4):167-168.
DeQuardo J.R., Tandon R. ECT in post-stroke major depression Convulsive Therapy. 1988;4(3):221-224.
Tandon R., Channabasavanna S.M., Greden J.F. CSF biochemical correlates of mixed affective states Acta Psychiatrica Scandinavica. 1988;78(3):289-297.
Tandon R., Greden J.F., Silk K.R. Treatment of negative schizophrenic symptoms with trihexyphenidyl Journal of Clinical Psychopharmacology. 1988;8(3):212-215.
Tandon R., Grunhaus L., Haskett R., Krugler T., Greden J. Relative efficacy of unilateral and bilateral electroconvulsive therapy in melancholia Convulsive Therapy. 1988;4(2):153-159.
Tandon R., Walden M., Falcon S. Catatonia as a manifestation of paraneoplastic encephalopathy Journal of Clinical Psychiatry. 1988;49(3):121-122.
Tandon R., Yaroch J., Falcon S. Hemochromatosis with episodic confusion. Journal of Clinical Psychiatry. 1988;49(7):284.
Tandon R. Letter to the Editor Acta Psychiatrica Scandinavica. 1987;76(6):732-732.
Tandon R., Greden J. Schneiderian first rank symptoms: Reconfirmation of high specificity for schizophrenia Acta Psychiatrica Scandinavica. 1987;75(4):392-396.
Tandon R., Greden J. Variety of effects of trihexyphenidyl (THP) on schizophrenic and non-schizophrenic abusers. Acta Psychiatrica Scandinavica. 1987;76(6):732.
Tandon R., Grunhaus L., Greden J. Imipramine and tinnitus Journal of Clinical Psychiatry. 1987;48(3):109-111.